MAP2K1 and osteoporosis: Among these drugs, DB00114 is an activator of GOT1, and most of the other drugs are inhibitors of ATP1A1, ATP6V1G2, HPRT1, MAP2K1 and PLK2. Many drugs targeting ATP1A1 are used for cardiovascular disease treatment, drugs targeting ATP6V1G2 are used for the treatment of osteoporosis and other bone diseases, drugs targeting GOT1 are used for nutritional supplementation, and several drugs targeting HPRT1 and MAP2K1 are used for the treatment of immune-related disease and cancer (Supplementary Table 3).